Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited VIVOTM non- invasive mapping 19/LO/03 Please Please 162140 257755 of Yes 03/07/2019 26 33 59 01/03/2019 05/05/2019 21/04/2019 15/05/2019 31/05/2019 31/05/2019 08 Select... Select... ventricula r arrhythmi a A Pilot Study to exPlOre the exisTence and impact of 19/LO/07 FRAILTY Please Please 162141 264744 Yes 20/08/2019 31 11 42 01/04/2019 09/07/2019 16/07/2019 24/07/2019 09/08/2019 09/08/2019 84 in Select... Select... patients over the age of 70 undergoin g cardiac interventi ons Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited "Pressure- controlled Intermitte nt Coronary Sinus 19/SC/00 Occlusion Please Please 162142 259683 Yes 23/09/2019 40 12 52 01/04/2019 02/08/2019 16/07/2019 14/08/2019 11/09/2019 16/09/2019 50 (PiCSO) in Select... Select... Acute Myocardi al Infarction (PiCSO- AMI-I)" Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Randomiz ed, Double- blind, Placebo- Controlle d, Crossover , Dose 19/NW/0 Please Please 162143 260431 Escalation Yes 18/09/2019 8 36 44 15/04/2019 05/08/2019 14/06/2019 01/08/2019 13/08/2019 13/08/2019 181 Select... Select... Study of BLU-5937 in Subjects with Unexplain ed or Refractor y Chronic Cough Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase IIB, Randomis ed, Double- Blinded, Placebo- Controlle d Study of the Efficacy and Safety of 18/LO/00 Intramyoc Please NHS 162144 226737 Yes 16/03/2020 12 97 109 20/11/2017 28/11/2019 18/03/2018 03/12/2019 10/12/2019 10/12/2019 20 ardial Select... Provider Injection of Allogenei c Human Immunom odulatory Progenito r (iMP) cells in Patients Undergoi ng Coronary Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase 3 study of the long- term safety of a triple combinati on therapy Yes - Date 19/NW/0 Please Please 162145 269907 of VX-445, Unavailab 37 28/08/2019 12/11/2019 06/11/2019 04/12/2019 19/12/2019 19/12/2019 540 Select... Select... tezacaftor le and ivacaftor in people with cystic fibrosis aged 12 and older Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A Phase 3 study of the efficacy, safety and the body?s effects on a triple combinati on Yes - Date 19/NW/0 Please Please 162146 269510 therapy Unavailab 31 12/02/2019 04/11/2019 04/11/2019 04/12/2019 05/12/2019 05/12/2019 506 Select... Select... of VX-445, le tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11 Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited A study to evaluate the effectiven ess and safety of VX 445/Tezac aftor/Ivac aftor in people with 19/LO/13 Please Please 162147 268820 Cystic Yes 10/02/2020 40 63 103 19/06/2019 30/10/2019 29/10/2019 13/11/2019 09/12/2019 09/12/2019 18 Select... Select... Fibrosis who are heterozyg ous for the F508del mutation and a gating or residual function mutation Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited "Positiona l Therapy for Obstructi ve Sleep Apnoea: a Randomis ed Controlle 19/YH/02 Please Please 162148 252494 d Trial to Yes 30/10/2019 0 22 22 17/06/2019 08/10/2019 24/07/2019 08/10/2019 08/10/2019 08/10/2019 22 Select... Select... assess the effect on Health and Wellbeing in Older and Younger People." Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited FIRST-line support for Assistanc e in Breathing in Children (FIRST- ABC): A master protocol of two 19/EE/01 randomis Please Please 162149 260536 Yes 03/09/2019 0 11 11 04/06/2019 23/08/2019 26/07/2019 23/08/2019 23/08/2019 30/08/2019 85 ed trials Select... Select... to evaluate the non- inferiority of high flow nasal cannula (HFNC) versus continuou s positive airway pressure Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited "SPACE FOR COPD? delivered as a maintena nce program me on Pulmonar y Rehabilita tion 19/EM/02 discharge: Please Please 162150 262581 Yes 15/11/2019 13 17 30 19/08/2019 16/10/2019 10/10/2019 10/10/2019 29/10/2019 29/10/2019 67 a Select... Select... randomis ed controlled trial evaluatin g the long- term effects on exercise tolerance and mental wellbeing Duration Duration Duration between Research Integrate between between First Date Site Ethics d Date of Date Site Date Site Reasons Participan Confirme HRA Date Site Non- Date Site Committe Research Name of First Selected Selected Date Site Date Site Date Site for delay t d and Approval Confirmed Confirmat Ready To e Applicatio Trial Participant and Date and First Invited Selected Confirmed correspon Recruited First Date By Sponsor ion Status Start Reference n System Recruited Site Participan d to: ? Participan Number Number Confirme t t d Recruited Recruited Randomiz ed, Double- Blind, Placebo- Controlle d, Dose- Ranging, Efficacy and Safety Study with 19/EM/01 Inhaled Please NHS 162151 260487 Yes 27/02/2020 35 183 218 13/03/2019 24/07/2019 17/06/2019 27/08/2019 28/08/2019 28/08/2019 01 RVT-1601 Select..